| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-03-20 | Kiadis Pharma (The Netherlands) | nomination | Cancer - Oncology - Hematological diseases | Nomination | ||
| 2017-03-20 | X-Chem (USA - MA) Astellas Pharma (Japan) | research collaboration | Collaboration agreement | |||
| 2017-03-17 | Daiichi Sankyo (Japan) Heptares Therapeutics (UK) | G protein-coupled receptor (GPCR) | pain | research development | CNS diseases | R&D agreement |
| 2017-03-17 | AstraZeneca (UK) Circassia (UK) | Tudorza® (aclidinium bromide inhalation powder) and Duaklir® (aclidinium bromide and formoterol) | chronic obstructive pulmonary disease (COPD) | development commercialisation | Lung diseases - Respiratory diseases | Development agreement |
| 2017-03-16 | Daiichi Sankyo (Japan) Mitsubishi UFJ Capital (Japan) National Institutes of Biomedical Innovation, Health and Nutrition (Japan) OiDE Adjubilee (Japan) | research | Cancer - Oncology | R&D agreement | ||
| 2017-03-16 | Kite Pharma (USA - CA) | nomination | Cancer - Oncology | Nomination | ||
| 2017-03-16 | PTC Therapeutics (USA - NJ) Marathon Pharmaceuticals (USA - IL) | Emflaza™ (deflazacort) | Duchenne muscular dystrophy | product acquisition | Rare diseases - Genetic diseases - Neuromuscular diseases | Product acquisition |
| 2017-03-16 | Biogen (USA - MA) | nomination | Nomination | |||
| 2017-03-16 | Beactica (Sweden) Uppsala University (Sweden) SciLifeLab (Sweden) | allosteric modulators of the epigenetic protein LSD1 | glioma | research - R&D | Cancer - Oncology | Research agreement |
| 2017-03-15 | Adaptimmune (UK) | nomination | Cancer - Oncology | Nomination | ||
| 2017-03-14 | AMO Pharma (UK) Ranedis Pharmaceuticals (USA - PA) | RND-001 | collaboration development | Rare diseases - Genetic diseases - CNS diseases -Neurodegenerative diseases | Development agreement | |
| 2017-03-14 | Crispr Therapeutics (Switzerland - UK) Casebia Therapeutics (USA - MA) MaxCyte (USA - MD) | CRISPR/Cas9-based therapies for hemoglobin-related diseases and severe combined immunodeficiency | licensing | Hematologic diseases - Genetic diseases - Rare diseases - Immunological diseases | Licensing agreement | |
| 2017-03-14 | Fortress Biotech (USA - NY) Cyprium Therapeutics (US - NY) | Cyprium Therapeutics (US - NY) | Menkes disease and related copper metabolism disorders | establishment of a new subsidiary in the US | Rare diseases - Genetic diseases - Metabolic diseases | Establishment of a new subsidiary in the US |
| 2017-03-13 | Celgene (USA - NJ) Agios Pharmaceuticals (USA -MA) | metabolic immuno-oncology programs | collaboration | Cancer - Oncology | Milestone | |
| 2017-03-13 | Mylan (USA - PA) Roche (Switzerland) | MYL-1401O - biosimilar version of trastuzumab | settlement - licensing | Cancer - Oncology | Licensing agreement | |
| 2017-03-13 | GlycoMimetics (USA - Md) | nomination | Cancer - Oncology | Nomination | ||
| 2017-03-13 | GSK (UK) | Gödöll? plant in Hungary | diphtheria, tetanus | construction of new premises | Infectious diseases | Construction of new premises |
| 2017-03-10 | Crispr Therapeutics (Switzerland - UK) Neon Therapeutics (USA - MA) | novel T cell therapies | R&D - research | Cancer - Oncology | Research agreement | |
| 2017-03-10 | Endocyte (USA - IN) Seattle Children's Research Institute (USA - WA) | small molecule drug conjugates platform in the chimeric antigen receptor T-cell (CAR T-cell) immunotherapy setting | development | Cancer - Oncology | Development agreement | |
| 2017-03-09 | Galapagos (Belgium) Pharnext (France) | synergistic drug combinations | neurodegenerative diseases, immunoinflammatory diseases | research - R&D | Neurodegenerative diseases - Neuroinflammatory diseases | Research agreement |
